Alexandra Oltova

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Journal: Haematologica
Published: July 31, 2018

Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.

Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.

Journal: Annals of hematology
Published: May 20, 2018

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.

Journal: Leukemia
Published: September 23, 2017

Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.

Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.

Journal: American journal of hematology
Published: June 28, 2017

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.

Journal: Oncotarget
Published: February 01, 2016

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.

Journal: American journal of hematology
Published: January 28, 2015

Frequent chromatin rearrangements in myelodysplastic syndromes--what stands behind?

Frequent chromatin rearrangements in myelodysplastic syndromes--what stands behind?

Journal: Folia biologica
Published: November 05, 2014

TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: August 13, 2014

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Journal: Leukemia
Published: January 29, 2014

Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis.

Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis.

Journal: Leukemia research
Published: August 31, 2013

Chromosome banding analysis of peripheral blood lymphocytes stimulated with IL2 and CpG oligonucleotide DSP30 in patients with chronic lymphocytic leukemia

Chromosome banding analysis of peripheral blood lymphocytes stimulated with IL2 and CpG oligonucleotide DSP30 in patients with chronic lymphocytic leukemia

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: August 22, 2013

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

Journal: Leukemia & lymphoma
Published: January 08, 2013
Showing 1-12 of 13

Last Updated: 09/26/2026